Comparison of prophylactic effect of venlafaxine and topiramate in patients with chronic migraine : An open label randomized controlled trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120227009157N8

Enrollment

100

Registered

2018-07-10

Start date

2018-06-22

Completion date

Unknown

Last updated

2018-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine. Migraine

Interventions

Intervention 1: Intervention group: Intervention group will receive 37.5 mg venlafaxine at the beginig of the intervention period and increase does up to 150 mg until 2 weeks. Intervention 2: Interven

Eligibility

Sex/Gender

All

Age

20 Years to 55 Years

Inclusion criteria

Inclusion criteria: Patients who met the ICHD-3 criteria Age 20-55 years

Exclusion criteria

Exclusion criteria: Taking migraine prophylactic drugs in the last 4 weeks Suffeing from renal, cardiovascular and liver diseases. Having major depression, bipolar disorder and psychosis Having hypertension or ocular hypertension Pregnancy or lactation

Design outcomes

Primary

Measure	Time frame
Number of migraine days. Timepoint: Before intervention and after 12 weeks intervention. Method of measurement: Headache diary.;Number of migraine attacks. Timepoint: Before intervention and after 12 weeks intervention. Method of measurement: Headache diary.;Maximum intensity of migraine attacks. Timepoint: Before intervention and after 12 weeks intervention. Method of measurement: Headache diary and Visual Analogue Scale.	—

Measure

Time frame

Number of migraine days. Timepoint: Before intervention and after 12 weeks intervention. Method of measurement: Headache diary.;Number of migraine attacks. Timepoint: Before intervention and after 12 weeks intervention. Method of measurement: Headache diary.;Maximum intensity of migraine attacks. Timepoint: Before intervention and after 12 weeks intervention. Method of measurement: Headache diary and Visual Analogue Scale.

—

Secondary

Measure	Time frame
Headache Duration in hours. Timepoint: Before the intervention and after the intervention period(12 weeks). Method of measurement: Headache diary.;Responder rate. Timepoint: After the intervention period(12 weeks). Method of measurement: Headache diary:30-50% decrease in primary endpoints relative to baseline.;Days of analgesic usage. Timepoint: Before the intervention and after the intervention period(12weeks). Method of measurement: Headache diary.;Health care outcomes/quality of life Recommendations. Timepoint: Before the intervention and after the intervention period(12 weeks). Method of measurement: HIT-6 score.	—

Measure

Time frame

Headache Duration in hours. Timepoint: Before the intervention and after the intervention period(12 weeks). Method of measurement: Headache diary.;Responder rate. Timepoint: After the intervention period(12 weeks). Method of measurement: Headache diary:30-50% decrease in primary endpoints relative to baseline.;Days of analgesic usage. Timepoint: Before the intervention and after the intervention period(12weeks). Method of measurement: Headache diary.;Health care outcomes/quality of life Recommendations. Timepoint: Before the intervention and after the intervention period(12 weeks). Method of measurement: HIT-6 score.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Samaneh Haghighi

Tehran University of Medical Sciences

haghighi_sa@yahoo.com+98 21 6312 1506

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026